Sophie Raynaud

Nice, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Journal: Blood

Published: August 19, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Journal: Blood

Published: August 19, 2025

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).

Journal: British journal of haematology

Published: February 11, 2024

Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.

Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.

Journal: EJHaem

Published: January 10, 2023

Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.

Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.

Journal: Nature communications

Published: December 07, 2022

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.

Journal: British journal of haematology

Published: November 27, 2022

Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia.

Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia.

Journal: Cancer medicine

Published: July 12, 2022

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Journal: Nature communications

Published: January 05, 2022

Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype.

Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype.

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 11, 2021

Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.

Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.

Journal: Journal of thrombosis and thrombolysis

Published: April 09, 2020

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Journal: Nature communications

Published: January 30, 2020

Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.

Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.

Journal: European journal of haematology

Published: November 11, 2019

Showing 1-12 of 34

Last Updated: 09/26/2026